66 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
-OXY-201, ODD in the EU, discussion with the US FDA regarding the XRX-OXY-301 clinical trial and possible initiation of special protocol assessment … trends, risks and uncertainties. Actual results in the future may differ materially from our present assessment of this information because future
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its … . We could be an “emerging growth company” for up to five years following the US IPO Offering. An independent assessment of the effectiveness of our
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
, initiation of special protocol assessment (“SPA”) discussions with the FDA and initiation of commercialization activities, if approved, for XORLOTM … in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as anticipated
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
– XRX-OXY-201, ODD in the EU, discussion with the US FDA regarding the XRX-OXY-301 clinical trial and possible initiation of special protocol assessment … , operating trends, risks and uncertainties. Actual results in the future may differ materially from our present assessment of this information because future
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its … 404. We could be an “emerging growth company” for up to five years following the US IPO Offering. An independent assessment of the effectiveness of our
424B3
0nk8nb
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
9f7ju3ftn rovvc
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
2kgsd61ftjus j3c5yc
22 Apr 24
XORTX Announces Publication of Key Research in ADPKD
7:00am
6-K
EX-99.1
b8cz1e0z
27 Mar 24
XORTX Announces New Clinical Advisory Board Member
7:42am
424B5
w90jf3crs q2z
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
gom 5avt4ywc
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
b0i5c wkatk6k3
25 Aug 23
Prospectus supplement
6:00am
424B3
s1ii5muyq7uo5vd
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
b7ebjavz
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
olqur8cuesn
14 Aug 23
Prospectus supplement
4:42pm
424B3
torj9evlxvi4
14 Aug 23
Prospectus supplement
4:40pm
POS AM
wfurqm1mjzd
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm